MiniMed Launches Japan's First Insulin Infusion Set Designed for Up to Seven Days of Wear
MiniMed Extended™ Infusion Set for insulin pump therapy is designed for up to 7-day wear

Reducing set changes by half and a simple three-step insertion process help simplify diabetes management

 

Tokyo, Japan. – September 16, 2026 - MiniMed announced the launch of the Extended™ Infusion Set in Japan, the first infusion set in Japan designed for up to seven days of wear. This development doubles the length of time an infusion set can be worn so users can safely stay on insulin pump technology with fewer interruptions and insertions1 while introducing enhanced convenience and comfort2 to their diabetes management routine.  

An infusion set is tubing that delivers insulin from an insulin pump to the body and typically requires a set change every two to three days. Designed specifically for use with MiniMed automated insulin delivery (AID) systems, the 7-day wear Extended™ Infusion Set may reduce replacement frequency by half, helping to ease the day-to-day burden for people living with diabetes and give their insertion sites more time to rest. Compared to traditional insulin therapy using multiple daily injections, this represents up to 96% fewer injections. Δ

The Extended™ Infusion Set uses new materials to maintain insulin flow and stability for up to seven days. Its redesigned tubing connector helps improve insulin stability and infusion-site reliability while reducing the risk of occlusions.1

A durable, skin-friendly adhesive is designed to remain comfortable and resist lifting throughout seven days of wear.2 An integrated inserter enables a simple three-step insertion process. This simplified process may make AID therapy easier to learn and start. Used with the infusion set, the Extended™ Reservoir is the only reservoir specifically tested and approved to maintain insulin safety and stability for up to seven days.3,4

Speaking about the launch of the Extended™ Infusion Set in Japan, Dr. Yuji Hirota, Associate Professor, Division of Diabetes and Endocrinology, Kobe University Graduate School of Medicine, commented “With conventional infusion sets requiring replacement every two to three days, people living with diabetes and their families often need to consider infusion set changes when planning travel, business trips, school events, and other everyday activities. For young children and older adults who require support with diabetes management, family members and caregivers frequently take responsibility for infusion set changes, making a reduction in replacement frequency particularly meaningful. By enabling wear for up to seven days, the Extended™ Infusion Set has the potential to substantially reduce the frequency of set changes. I believe this may help lessen the mental burden and day-to-day effort associated with diabetes management for people living with diabetes, their families, and caregivers, while supporting a more natural and greater flexible daily life.

In addition, the simplified insertion process and reduced replacement frequency may provide reassurance for individuals who have been hesitant to adopt AID systems. I hope innovations such as these will encourage greater adoption of AID therapy, allowing more people to benefit from improved glucose management and the advantages of advanced diabetes technologies.”

In clinical studies of the Extended™ Infusion Set, insulin stability as well as infusion set safety and performance were maintained for up to seven days of use.3,4 Participants using the Extended™ Infusion Set reported high levels of satisfaction with ease of use and comfort. The extended wear capability of up to seven days was also viewed positively as a feature that may help reduce some of the day-to-day demands associated with insulin pump therapy.5

“The Extended™ Infusion Set reflects MiniMed Japan’s commitment to advancing diabetes technology around people’s needs", said Mitsuyo Oka, Managing Director of MiniMed Japan. "By simplifying therapy, reducing set changes, and expanding treatment choice, these developments can ease the daily burden of diabetes and help more people live life on their own terms, rather than having to organize their lives around diabetes treatment.”

Approximately 92,000 people are estimated to be living with type 1 diabetes in Japan.6 As the condition requires ongoing, long-term management, people living with type 1 diabetes and their families face daily treatment demands over many years.

Due in part to the relatively small patient population, public understanding of type 1 diabetes remains limited. As a result, misconceptions and lack of awareness can sometimes create challenges in schools, workplaces, and other settings.

 

About MiniMed
MiniMed is a global leader in insulin delivery, constantly advancing therapies that support people with diabetes in more than 80 countries. Our full-stack, integrated ecosystem, including our insulin delivery systems, CGMs, algorithms, and easy-to-use app experience, is designed to work seamlessly together, supported by white-glove, wrap-around service. For over 40 years, we've pioneered therapies people can rely on by anticipating needs, reducing burden, and helping make life with diabetes easier. Our mission is to make every day a better day for people with diabetes.

Any forward-looking statements are subject to risks and uncertainties such as those described in MiniMed's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

 

Δ Assumes 4 injections per day for 30 days and one infusion set change every seven days.

References:

  1. Zhang G, et al. Development of the Extended Infusion Set and Its Mechanism of Action. J Diabetes Sci Technol. 2024;18(2):454-459. doi:10.1177/19322968221112120
  2. Zhang G, et al. 986-P - Assessment of adhesive patches for an extended wear infusion set. 80th ADA International Conference, June 2020.
  3. Ilany J, et al. Abstract 416 - Clinical study of a new extended wear infusion set design. 13th ATTD International Conference. February 2020.
  4. Zhang JY, et al. Advances in Insulin Pump Infusion Sets Symposium Report. J Diabetes Sci Technol. 2021;15(3):705–709.
  5. Brazg R, et al, Diabetes Technol Ther. 2022; Mar 24. doi: 10.1089/dia.2021.0540.
  6. 2017 Health and Labour Sciences Research Grant (Tashiro Study Group), Ministry of Health, Labour and Welfare, Japan.

 

Contacts:

Andrew Crawford
Public Relations
+41 79 378 1932

Ryan Weisspfenning
Investor Relations
+1-763-505-4626

(opens in a new window)